Is QIAGEN getting acquired?
QIAGEN is not engaged in any active merger talks or acquisition proceedings, operating entirely independently following the withdrawal of prior takeover interest from larger life sciences conglomerates. The corporate leadership team remains focused on expanding its molecular testing portfolio, scaling digital diagnostics platforms, and maximizing long-term shareholder value through organic development and targeted smaller partnerships.
Related FAQs
QIAGEN traces its direct historical origins back to Germany, where it was established by scientific founders and where its primary operational headquarters, major research laboratories, and extensive manufacturing facilities remain heavily concentrat...
QIAGEN operates its main United States subsidiary and operational command center in Germantown, Maryland, where its primary administrative offices and advanced life sciences laboratories are anchored.
The corporate name QIAGEN does not formally stand for an acronym spelled out from initial letters; instead, it is an invented proprietary brand name combining scientific roots associated with gene technology and molecular testing.
QIAGEN N.V. is a leading global provider of molecular testing solutions and sample preparation technologies, offering a comprehensive portfolio designed for clinical diagnostics, academic research, and pharmaceutical development.
Siemens competes across diverse industrial sectors, meaning its biggest rivals vary depending on the business unit.
QIAGEN sells a comprehensive portfolio of advanced sample technologies, assay kits, diagnostic instruments, and bioinformatics software designed for molecular testing and biological research.
QIAGEN is not currently the target of any active corporate buyout or acquisition agreements.
QIAGEN N.V. reports annual net sales of approximately $2 billion USD (with trailing twelve-month revenues running over ₹187 billion to ₹201 billion in equivalent international tracking metrics).
Royal Bank of Canada (RBC) completed a massive cross-border acquisition of City National Bank (CNB)—often referred to as the bank to the stars in Los Angeles—for a total purchase consideration of approximately 5 billion US dollars in cash and stock.
The corporate name QIAGEN does not translate to a common dictionary word; rather, it is a proprietary portmanteau brand name coined by its founders during the company's establishment to reflect its core focus on gene analysis and molecular biology.
QinetiQ specializes primarily in defense technology research, test and evaluation, systems engineering, and advanced scientific consulting rather than mass-producing traditional firearms or munitions.
Categorizing QIAGEN as strictly German or Dutch involves recognizing its dual corporate structure, as its legal holding parent is officially registered and headquartered in Venlo, Netherlands, while its primary executive management, historical roots,...
QIAGEN drives its corporate expansion and long-term financial strategy through five core growth pillars that represent areas of established market leadership and high scalability.
QIAGEN N.V.
Yes, in 2026, the private equity firm Thoma Bravo submitted an offer to acquire Clearwater Analytics, a provider of investment management software.
The stock ticker QGEN represents the equity shares of QIAGEN N.V., a leading global provider of molecular testing and sample technology solutions traded on international stock exchanges.
QIAGEN N.V. maintains its official global corporate holding headquarters in Venlo, Netherlands, making it legally structured and registered as a Dutch corporate entity.
Interest rates offered by community financial institutions like the Bank of Kampsville encompass diverse deposit products, including standard savings accounts, tiered money market accounts, and fixed-term certificates of deposit across various maturi...
The name QinetiQ, the British multinational defense technology company, is pronounced "kwi-NET-ik." It is a three-syllable word. The first syllable, "kwi," starts with a crisp "kw" sound, like in "quick.
While specific real-time data for Qorvo's market capitalization as of July 2026 was not explicitly detailed in the provided search results, it remains a publicly traded semiconductor company.
Securities trading under the ticker symbol QGEN on the New York Stock Exchange represent ordinary common shares of QIAGEN N.V. rather than a traditional American Depositary Receipt structure.
Biogen is navigating a transitional phase characterized by disciplined cost-structure optimization, strategic asset acquisitions, and portfolio diversification away from its aging legacy multiple sclerosis blockbusters.
Market consensus evaluations from biotechnology and healthcare equity research analysts generally view QIAGEN as a solid, defensive long-term investment holding.
QIAGEN N.V. shares (traded under the ticker QGEN) trade at a live market price of approximately $42.08 per share.
Equity research analysts evaluate QIAGEN N.V. with favorable, resilient long-term growth prospects, anchored by its global market leadership in molecular diagnostics, sample preparation technologies, and life sciences research tools.